If you are researching fertility treatment, you have probably seen bold claims about PGT: that it guarantees a healthy baby, speeds up pregnancy for everyone, or is only for older couples. Most of those claims are incomplete at best. The truth is more useful. This guide breaks down PGT Myths vs Facts in a practical, evidence-based way so you can understand what Preimplantation Genetic Testing does, where it helps, where it has limits, and how to evaluate it if you are considering PGT in Nepal or treatment at an ivf center in Nepal. At clinics such as Slavica IVF and Research Center in Sinamangal, Kathmandu, PGT is offered as part of advanced IVF care.

Direct definition: Preimplantation Genetic Testing, or PGT, is a laboratory test used during IVF to analyze embryos before transfer. It can help identify certain chromosomal abnormalities or specific inherited genetic conditions, but it does not guarantee implantation, pregnancy, or the birth of a healthy baby.
PGT matters because embryo appearance alone cannot reveal all chromosomal or single-gene problems. In selected patients, testing can improve embryo selection, reduce the chance of transferring embryos affected by specific conditions, and support more informed treatment planning. But the strongest evidence varies by PGT type and by patient profile. ASRM states that the value of routine PGT-A for all IVF patients remains unclear, while the clinical utility of PGT-M and PGT-SR is more firmly established in the right indications.
| Myth | Fact | What it means for patients |
| PGT guarantees a healthy baby | PGT reduces specific risks, but it cannot rule out every medical condition or guarantee birth outcomes | Prenatal screening and diagnosis are still recommended when appropriate |
| PGT is only for women over 35 | Age is one factor, but PGT may also be relevant for recurrent miscarriage, repeated IVF failure, translocations, or known inherited disease | The right question is not age alone, but indication and history |
| PGT-A helps everyone doing IVF | Evidence for universal benefit is mixed; it may help some groups more than others | Blanket use is not the same as evidence-based use |
| PGT can detect all genetic diseases | It tests for selected abnormalities depending on the method used | A normal result is reassuring, not absolute |
| If an embryo is labeled abnormal, it can never lead to a baby | Embryo biology is more complex than a simple pass/fail label, especially with mosaic results | Results need specialist interpretation and counseling |
| PGT replaces prenatal testing | It does not | Pregnancy follow-up remains essential |
| PGT damages embryos and should always be avoided | Modern biopsy techniques are widely used, but no intervention is entirely risk-free | Lab quality and embryology expertise matter a great deal |
Fact: PGT can improve decision-making, but it does not guarantee implantation, ongoing pregnancy, or live birth. IVF success also depends on maternal age, egg quality, sperm factors, uterine conditions, embryo development, and laboratory performance. ASRM’s 2024 committee opinion specifically notes that routine PGT-A has not shown universal benefit across all patients.
PGT improves selection in some cases; it does not guarantee success.
Fact: Advanced maternal age is an important reason PGT may be discussed, especially for aneuploidy risk, but it is not the only one. PGT may also be relevant when there is:
“PGT should be matched to the patient’s reproductive problem, not sold as a standard add-on.”
Fact: PGT can reduce the chance of transferring embryos with the specific abnormalities being tested, but it cannot exclude every birth defect, developmental issue, or future medical problem. ACOG emphasizes that because PGT is not uniformly accurate or comprehensive, prenatal screening and diagnostic testing should still be offered when pregnancy occurs.
A normal PGT result lowers selected risks. It does not eliminate all risk.
For patients exploring ivf in Nepal, the real value of PGT is not that it promises certainty. The value is that it can reduce avoidable uncertainty in carefully selected situations. That distinction matters because unrealistic expectations lead to poor decisions and disappointment.

In an ivf clinic in nepal, PGT is not a standalone test. It is part of a larger IVF workflow.
The patients most likely to benefit are usually those with a defined clinical reason.
A good fertility center should not start with “Do you want PGT?” It should start with “What reproductive risk are we trying to reduce?” That is the question that separates medical judgment from sales language.
One reason the topic of PGT Myths vs Facts is so important is that the public conversation often treats all forms of PGT as equal. They are not.
| PGT type | Best-supported use | Evidence nuance |
| PGT-M | Avoiding transmission of a known single-gene disorder | Strong clinical value when the familial mutation is defined |
| PGT-SR | For parental structural rearrangements | Well-established in indicated cases |
| PGT-A | Screening for chromosome number abnormalities | Use is common, but routine use for all IVF patients remains debated |
This is where many fertility articles fail. They imply that because one type of PGT is clearly useful, all types are equally proven in all scenarios. That is not supported by current guidance.
For anyone researching PGT in Nepal, the better decision usually comes from asking sharper questions, not just comparing package prices.

At Slavica IVF and Research Center, PGT is listed among the center’s core fertility services in Kathmandu. The clinic’s team pages identify Dr. Ajaya Jang Kunwar, Chairman and Clinical Embryologist, with over 20 years of teaching and research experience and specialized training in embryo biopsy, Dr. Nikita Dhakal, MD in Obstetrics and Gynaecology and IVF Specialist, with fellowship training in fertility treatment in New Delhi and prior IVF leadership experience in Kathmandu and Dr. Nilam Thakur Kunwar, a highly accomplished Clinical Geneticist with an MBBS degree from Kathmandu Medical College Teaching Hospital and an MSc in Clinical Genetics from the University of Colombo, Sri Lanka. Those details matter because PGT outcomes depend heavily on specialist counseling, embryology quality, and the accuracy of test interpretation.
The biggest myth is that PGT guarantees a healthy baby. It does not. It can reduce selected genetic risks and improve embryo selection in some cases, but it cannot guarantee pregnancy, live birth, or perfect health.
No. Routine use for every patient is not supported equally across all scenarios. The benefit depends on age, reproductive history, family genetics, and the specific type of PGT being considered.
Yes. PGT is offered by fertility centers in Nepal, including Slavica IVF and Research Center, which lists Preimplantation Genetic Testing among its services.
No. ACOG recommends that prenatal screening and diagnostic testing still be offered because PGT is not fully comprehensive or uniformly accurate.
No. PGT only tests for the conditions or abnormalities targeted by the method being used. It is powerful, but not universal.
No. PGT-A screens chromosome number. PGT-M tests for a known single-gene disorder. They answer different clinical questions and should not be confused.
Patients with a known inherited condition, a parental translocation, selected recurrent miscarriage history, or age-related aneuploidy concerns may be candidates after proper fertility and genetic counseling.
The most accurate way to think about PGT Myths vs Facts is this: PGT is not magic, and it is not meaningless. It is a targeted decision tool. In the right case, it can be highly valuable. In the wrong case, it can add cost, complexity, and false confidence.
